Jump to content
SurvivingAntidepressants.org is temporarily closed to new registrations until 1 April ×

Black, 2000 Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.


Altostrata

Recommended Posts

  • Administrator

J Psychiatry Neurosci. 2000 May;25(3):255-61.

Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Black K, Shea C, Dursun S, Kutcher S.

 

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/10863885

Free full text at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1407715/?tool=pubmed

and http://www.mediafire.com/?1kgew9ccf6vuxqg

 

OBJECTIVE:

 

To establish specific criteria by which selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome may be identified.

DATA SOURCES:

 

MEDLINE and PSYCHLIT databases were searched for case reports published from 1986 to 1997 inclusive, and references of relevant articles were also searched.

STUDY SELECTION:

 

Forty-six case reports of symptoms following the discontinuation of fluoxetine, fluvoxamine, paroxetine or sertraline were selected. Three studies of SSRI discontinuation were also reviewed.

 

DATA EXTRACTION:

 

Demographic and treatment information, as well as the timing, duration, number, nature and frequency of dicontinuation symptoms.

 

DATA SYNTHESIS:

 

Paroxetine was most frequently implicated. The drug had been tapered in half of the cases. In some cases, symptom onset began during taper, whereas, in most cases, symptoms began within 1 to 3 days of drug discontinuation. Fifty-three different symptoms were reported, with dizziness being the most common. Other common symptoms were nausea or emesis, fatigue, headache, gait instability and insomnia. Shock-like sensations, paresthesia and visual disturbances were the most rare. Without intervention, symptoms persisted for more than a week in half of the cases. In cases in which the SSRI was restarted, symptoms resolved within 72 hours. In some cases, withdrawal symptoms recurred when the same SSRI was again discontinued.

 

CONCLUSIONS:

 

Findings were used to construct diagnostic criteria for the SSRI discontinuation syndrome. These criteria are 2 or more of the following symptoms developing within 1 to 7 days of discontinuation or reduction in dosage of an SSRI after at least 1 month's use, when these symptoms cause clinically significant distress or impairment and are not due to a general medical condition or recurrence of a mental disorder: dizziness, light-headedness, vertigo or feeling faint; shock-like sensations or paresthesia; anxiety; diarrhea; fatigue; gait instability; headache; insomnia; irritability; nausea or emesis; tremor; and visual disturbances.

 

---------------

Adapted from the paper:

 

TABLE 1: Symptoms occurring after discontinuing an SSRI (only those occurring in more than 5% of cases are included)

 

Symptom with percentage of cases reporting (n=46)

 

NEUROLOGICAL

Dizziness/Light-headedness/

Vertigo..................65.2

Gait instability...............21.7

Shock-like sensations..........13.0

Paresthesia....................10.9

Visual disturbance.............10.9

Loss of balance.................8.7

 

SOMATIC

Nausea/emesis..................37.0

Fatigue........................26.1

Headache.......................23.9

Diarrhea.......................10.9

Myalgia.........................8.7

Chills..........................6.5

 

MENTAL

Insomnia.......................17.4

Agitation.......................8.7

Impaired concentration..........8.7

Vivid dreams or nightmares......8.7

Depersonalization/detachment/

dissociation................6.5

Irritability....................6.5

Suicidal thoughts or behaviour..6.5

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

×
×
  • Create New...

Important Information

Terms of Use Privacy Policy